AI-Generated Filing Summaries

TSMC disclosed minor increases in shareholdings by Vice Presidents Jonathan Lee (+225 to 486,022 shares), B.Z. Tien (+2,000 to 5,051 shares), and Lipen Yuan (+420 to 3,600 shares) as of February 28, 2026; NT$3.5 billion fixed-income investment acquisition and NT$1.2 billion machinery disposition; and board-approved capital appropriations of US$18,921 million for advanced technology, US$4,670 million for packaging/specialty tech, and US$21,372 million for real estate. These provide transparency on insider ownership, asset adjustments, and expansion investments.

Brand Engagement Network, Inc. disclosed that Bernard Puckett will step down as Chairman and resign from the Board of Directors effective March 31, 2026, following the end of his two-year term, with no disagreements on company matters. The Board appointed Jon Leibowitz as the new Chairman effective April 1, 2026.

Brand Engagement Network, Inc. disclosed that Bernard Puckett will step down as Chairman and resign from the Board of Directors effective March 31, 2026, following the end of his two-year term, with no disagreements on company matters. The Board appointed Jon Leibowitz as the new Chairman effective April 1, 2026.

On Holding AG announced co-founders David Allemann and Caspar Coppetti will serve as Co-CEOs effective May 1, 2026, succeeding Martin Hoffmann who steps down after 13 years as CFO and 5 as CEO. Scott Maguire is promoted to President & COO, Frank Sluis joins as CFO, restructuring leadership to align founder vision with execution for global growth.

Rentokil Initial plc filed a Form 6-K on 2026-03-25 with Items listed as N/A and Exhibit 99.1 attached as a PDF document.

Rentokil Initial plc filed a Form 6-K on 2026-03-25 with Items listed as N/A and Exhibit 99.1 attached as a PDF document.

Prudential plc purchased 364,573 ordinary shares of 5 pence each from JP Morgan Securities plc on 24 March 2026 at an average price of £10.6561 per share (lowest £10.5650, highest £10.7550). The company intends to cancel the shares, resulting in 2,528,841,259 shares in issue and total voting rights, for use as denominator under FCA Disclosure Guidance and Transparency Rules.

Prudential plc purchased 364,573 ordinary shares of 5 pence each from JP Morgan Securities plc on 24 March 2026 at an average price of £10.6561 per share (lowest £10.5650, highest £10.7550). The company intends to cancel the shares, resulting in 2,528,841,259 shares in issue and total voting rights, for use as denominator under FCA Disclosure Guidance and Transparency Rules.

Amaze Holdings, Inc. uploaded an investor presentation dated March 24, 2026, to its website, which is furnished as Exhibit 99.1 under Item 7.01 of this Form 8-K as a Regulation FD Disclosure. Item 7.01, including Exhibit 99.1, is not deemed 'filed' for purposes of Section 18 of the Exchange Act or incorporated by reference into other filings.

Viomi Technology Co., Ltd announced unaudited financial results for the second half and full year ended December 31, 2025, with full year net revenues of RMB2,428.2 million, up 14.6% from RMB2,119.0 million in 2024, and net income attributable to ordinary shareholders of RMB141.6 million. The company declared a special cash dividend of US$0.022 per ordinary share and US$0.066 per ADS.

Zedge, Inc. announced that its Board of Directors has declared a quarterly cash dividend of $0.02 per share of class B common stock, a 25% increase from $0.016 per share, payable on or about April 15, 2026 to stockholders of record as of April 6, 2026. This reflects confidence in business prospects, strong free cash flow generation including 31% year-over-year increase in Q2, and a debt-free balance sheet with $19.1 million in cash.

Amaze Holdings, Inc. issued a shareholder letter detailing the transition from 2025 stabilization to scaling the Creator Commerce Flywheel, highlighting data as a core asset, a new distribution partnership with LA Times Studios, Food Channel integration, and 2026 priorities for growth. This Reg FD disclosure provides strategic updates to inform investors on the company's evolving position in creator commerce.

Ingredion Incorporated elected Jason Payant as Interim Chief Financial Officer effective April 1, 2026, succeeding James D. Gray who resigns as Executive Vice President and Chief Financial Officer effective March 31, 2026. Payant, age 55 and with the Company since 2012, will receive monthly cash compensation of $25,000 in addition to his pre-existing compensation and benefits.

GSK plc announces it purchased 500,000 ordinary shares of 31¼ pence each on 24 March 2026 through BNP Paribas SA, at a volume-weighted average price of 1,949.05 GBp (lowest 1,933.00p, highest 1,967.00p), to be held as treasury shares under its existing buyback programme. Post-purchase, treasury shares total 254,402,615 (6.26% of voting rights) with 4,061,773,663 voting rights.

GSK plc announces it purchased 500,000 ordinary shares of 31¼ pence each on 24 March 2026 through BNP Paribas SA, at a volume-weighted average price of 1,949.05 GBp (lowest 1,933.00p, highest 1,967.00p), to be held as treasury shares under its existing buyback programme. Post-purchase, treasury shares total 254,402,615 (6.26% of voting rights) with 4,061,773,663 voting rights.

HBT Financial, Inc. and Heartland Bank and Trust Company appointed Michael J. Morton to their Boards of Directors, effective April 1, 2026, following a recommendation from the Nominating and Corporate Governance Committee. Mr. Morton, with nearly 40 years of banking experience including roles at BMO and MB Financial, will serve an initial term expiring at the 2026 Annual Meeting of Stockholders.

Kiora Pharmaceuticals, Inc. (KPRX) reported a net loss of $10.8 million for FY 2025 ending December 31, 2025, a reversal from the $3.6 million net income in FY 2024 driven by the $16 million upfront from TOI partnership. Total revenue was $0, with collaboration and grant revenue at $0. Key drivers of the loss included research and development expenses of $10.8 million, general and administrative expenses of $5.7 million, partially offset by collaboration credits of $7.1 million and a $4.6 million in-process R&D impairment. Total operating expenses were $12.8 million, resulting in an operating loss of $12.8 million before $714K other income net. Loss before tax was $12.1 million, with $1.3 million tax expense. Basic EPS was -$3 on 4.2 million weighted shares. Balance sheet: total assets $24.3 million, cash and equivalents $8.7 million, short-term investments $8.4 million, total liabilities $8.1 million, equity $16.1 million. Cash flows: operating -$10.0 million, investing +$14.4 million from marketable securities maturities, financing +$266K from warrant exercises, net cash increase $4.9 million. Forward-looking, Phase 2 trials for KIO-301 (ABACUS-2) and KIO-104 (KLARITY) ongoing, with TOI funding R&D costs and potential $285 million milestones, Senju option for Asia adding $1.25 million upfront and up to $109.5 million more.

Majority stockholders holding at least 66 2/3% voting power removed four directors and the CEO and CFO on March 20, 2026, appointing Mr. Youngjik Cho as CEO and Chairman, Mr. Minguk Ji and Mr. Junyoung Yu as directors, and Mr. Yu as Secretary. They amended bylaws to allow majority stockholders to fill board vacancies and approve bylaw changes, amid concerns over a prior merger with MindWave.

Kiora Pharmaceuticals reported fourth-quarter and full-year 2025 financial results, including a net loss of $10.8 million for the year compared to net income of $3.6 million in 2024, and ended the year with $17.1 million in cash, cash equivalents, and short-term investments. The company advanced Phase 2 clinical trials for KIO-301 in retinitis pigmentosa and KIO-104 in macular edema, with cash expected to fund operations into late 2027.

Dana Incorporated hosted its 2026 Capital Markets Day on March 25, 2026, in New York City, where leadership outlined the Dana 2030 strategy, including targets of approximately $10 billion in annual sales by 2030, adjusted EBITDA margins of 14-15%, adjusted free cash flow margin of 6%, and up to $2 billion in cumulative share repurchases through 2030. This provides investors with the company's long-term growth, margin expansion, and capital return plans.

Chewy, Inc. announced fiscal fourth quarter and full year 2025 financial results ended February 1, 2026, with full year net sales of $12.60 billion, up 6.2 percent year over year, gross margin expansion to 29.8 percent, net income of $222.8 million, and Adjusted EBITDA of $719.2 million. Q4 net sales reached $3.26 billion, up 0.5 percent year over year, with record free cash flow of $562 million for the year.

Energous Corporation reported fiscal year 2025 revenue of $5.6 million, a 633% increase from $0.8 million in 2024, marking the highest annual revenue in company history and fourth consecutive quarter of growth. GAAP net loss improved 48% to $9.6 million, the lowest since 2013, with $10.4 million in cash as of December 31, 2025.

Cognyte Software Ltd. reported Q4 FYE26 revenue of $106.2 million (up 12.4% YoY) and FYE26 revenue of $400.0 million (up 14.1% YoY), with GAAP operating income of $5.2 million and $13.3 million respectively, and positive GAAP net income in both periods. The company guides FYE27 revenue to $448 million (+/- 3%) with Adjusted EBITDA of $68 million and expanded its share repurchase program by $20 million.

VersaBank announced its 2026 Annual and Special Meeting of Shareholders will be held on April 8, 2026, at 10:30 a.m. ET at the VersaBank Innovation Centre of Excellence, 1979 Otter Place, London, Ontario. The meeting will be live-streamed on the Bank's website, with an archive available; live-stream attendees cannot vote and must submit proxies by 10:30 a.m. ET on April 6, 2026 to Odyssey Trust Company.

KNOT Offshore Partners LP reported Q4 2025 revenues of $96.5 million, operating income of $8.4 million after a $20.3 million non-cash impairment on the Bodil Knutsen, and net loss of $6.2 million, with adjusted figures showing operating income of $28.6 million and net income of $14.0 million. The Partnership declared a $0.026 per common unit distribution and terminated discussions on an acquisition proposal from Knutsen NYK.

Maze Therapeutics, Inc. (MAZE) reported a net loss of $131.1 million for FY 2025 ending December 31, 2025, compared to net income of $52.2 million in FY 2024, primarily due to the absence of $167.5 million in license revenue recognized in 2024 from agreements with Shionogi, Trace, and Neurocrine. Operating expenses rose to $142.9 million from $109.9 million YoY, driven by increased R&D ($108.4 million, +$24.9 million) from Phase 2 trials for MZE829 and Phase 1 for MZE782, and G&A ($34.5 million, +$8.0 million) from public company costs. Cash position strengthened to $360.0 million (cash equivalents $189.2 million, marketable securities $170.8 million), up from prior periods via $127.8 million IPO net proceeds and $141.3 million private placement. Total assets reached $397.1 million with stockholders' equity at $355.0 million. Cash used in operations was $111.9 million vs. provided $76.0 million YoY; investing used $171.0 million on securities; financing provided $275.3 million. Positive Phase 2 topline for MZE829 in AMKD (35.6% mean uACR reduction) and Phase 1 for MZE782 support pipeline advancement, with cash runway beyond one year. Forward-looking, focus on pivotal MZE829 development and Phase 2 MZE782 trials amid biotech risks.

Maze Therapeutics reported fourth quarter and full year 2025 financial results with $360.0 million in cash supporting operations into 2028, announced positive Phase 2 HORIZON topline data for MZE829 showing 35.6% mean uACR reduction in broad AMKD patients, and appointed Neil Kumar as a Class I director effective March 27, 2026. These disclosures provide clinical proof-of-concept, financial visibility, and strengthened board expertise.

Noah Holdings Limited announced unaudited U.S. GAAP consolidated annual results for the year ended December 31, 2025, reporting net revenues of RMB 2,610.2 million (up 0.4% from 2024) and net income attributable to shareholders of RMB 558.9 million (up 17.5% from 2024). The company declared a final dividend and special dividend of RMB 0.933 per share each, proposed amendments to its memorandum and articles of association, and disclosed multiple share repurchases of ADSs under its 2025 repurchase mandate.

Picard Medical, Inc. issued a press release announcing financial results for the fiscal year ended December 31, 2025, reporting total revenue of $4.94 million, up 12.5% from $4.39 million in 2024, product revenue of $4.75 million, operating loss of $(13.3) million, and net loss of $(27.0) million. Cash, cash equivalents, and restricted cash totaled $11.5 million at year-end following $27.1 million in net financing proceeds.

KalVista Pharmaceuticals reported financial results for the eight-month transition period ended December 31, 2025, including $49.1 million global net product revenue from EKTERLY and cash, cash equivalents and marketable securities of $300.2 million. Updates highlighted rapid US adoption with 1,702 patient start forms through February 2026 and EKTERLY launch in Japan.